PL1648505T3 - Frakcja Quil A o niskiej toksyczności i jej zastosowanie - Google Patents

Frakcja Quil A o niskiej toksyczności i jej zastosowanie

Info

Publication number
PL1648505T3
PL1648505T3 PL04749076T PL04749076T PL1648505T3 PL 1648505 T3 PL1648505 T3 PL 1648505T3 PL 04749076 T PL04749076 T PL 04749076T PL 04749076 T PL04749076 T PL 04749076T PL 1648505 T3 PL1648505 T3 PL 1648505T3
Authority
PL
Poland
Prior art keywords
quil
fraction
adjuvant
lps
derivatives
Prior art date
Application number
PL04749076T
Other languages
English (en)
Inventor
Bror Morein
Bengtsson Karin Lövgren
Jill Ekström
Katarina Ranlund
Kefie Hu
Original Assignee
Isconova Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isconova Ab filed Critical Isconova Ab
Publication of PL1648505T3 publication Critical patent/PL1648505T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
PL04749076T 2003-07-07 2004-07-07 Frakcja Quil A o niskiej toksyczności i jej zastosowanie PL1648505T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0301998A SE0301998D0 (sv) 2003-07-07 2003-07-07 Quil A fraction with low toxicity and use thereof
EP04749076A EP1648505B1 (en) 2003-07-07 2004-07-07 Quil a fraction with low toxicity and use thereof
PCT/SE2004/001038 WO2005002620A1 (en) 2003-07-07 2004-07-07 Quil a fraction with low toxicity and use thereof

Publications (1)

Publication Number Publication Date
PL1648505T3 true PL1648505T3 (pl) 2010-02-26

Family

ID=27731119

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04749076T PL1648505T3 (pl) 2003-07-07 2004-07-07 Frakcja Quil A o niskiej toksyczności i jej zastosowanie

Country Status (15)

Country Link
US (8) US8821881B2 (pl)
EP (1) EP1648505B1 (pl)
JP (1) JP4731475B2 (pl)
AT (1) ATE442164T1 (pl)
AU (1) AU2004254152B2 (pl)
BR (1) BRPI0412444B8 (pl)
CA (1) CA2529363C (pl)
DE (1) DE602004023089D1 (pl)
DK (1) DK1648505T3 (pl)
ES (1) ES2331952T3 (pl)
NZ (1) NZ544299A (pl)
PL (1) PL1648505T3 (pl)
SE (1) SE0301998D0 (pl)
WO (1) WO2005002620A1 (pl)
ZA (1) ZA200600151B (pl)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1104306B1 (en) * 1998-08-10 2006-01-11 Antigenics Inc. Compositions of cpg and saponin adjuvants and methods of use thereof
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (sv) * 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
CN101107009B (zh) * 2005-01-20 2014-08-06 伊斯克诺瓦公司 包含纤连蛋白结合蛋白或纤连蛋白结合肽的疫苗组合物
EP1764369A1 (de) * 2005-09-16 2007-03-21 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Vakzine enthaltend trunkiertes HBV core protein plus Saponin-basierendes Adjuvants
CA2646349A1 (en) 2006-03-24 2007-10-04 Novartis Vaccines And Diagnostics Gmbh & Co Kg Storage of influenza vaccines without refrigeration
US20100015168A1 (en) 2006-06-09 2010-01-21 Novartis Ag Immunogenic compositions for streptococcus agalactiae
WO2008031878A1 (en) * 2006-09-15 2008-03-20 Rhein Biotech Gesellschaft für neue Biotechnologische Prozesse und Produkte mbH A composition for therapy and/or for prophylaxis of hbv-infections and hbv-mediated diseases
EP1902727A1 (de) * 2006-09-22 2008-03-26 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Vakzine enthaltend trunkiertes HBV core protein plus Saponin-basierendes Adjuvants
AU2007322424B2 (en) * 2006-11-20 2013-05-16 Duecom Use of lipid containing particles comprising quillaja saponins for the treatment of cancer
CA2692200A1 (en) 2007-06-27 2008-12-31 Novartis Ag Low-additive influenza vaccines
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
HUE028921T2 (en) * 2008-06-27 2017-01-30 Zoetis Services Llc New adjuvant preparations
CA2766285A1 (en) * 2009-07-10 2011-01-13 Isconova Ab New composition
CA2808556A1 (en) 2010-09-20 2012-03-29 Crucell Holland B.V. Therapeutic vaccination against active tuberculosis
EP2750683B2 (en) 2011-10-03 2021-01-06 Croda International PLC Nanoparticles, process for preparation and use thereof as carrier for amphipatic of hydrophobic molecules in fields of medicine including cancer treatment and food related compounds
SG11201402633UA (en) 2011-11-28 2014-09-26 Crucell Holland Bv Influenza virus vaccines and uses thereof
SG11201405228VA (en) 2012-03-12 2014-11-27 Crucell Holland Bv Batches of recombinant adenovirus with altered terminal ends
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
EP2827895B1 (en) 2012-03-22 2017-08-09 Janssen Vaccines & Prevention B.V. Vaccine against rsv
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
ES2959258T3 (es) 2013-02-07 2024-02-22 Childrens Medical Center Antígenos proteicos que proporcionan protección contra la colonización y/o la enfermedad neumocócicas
SG11201506858SA (en) 2013-03-08 2015-09-29 Crucell Holland Bv Acellular pertussis vaccine
WO2014163558A1 (en) 2013-04-01 2014-10-09 Moreinx Ab Nanoparticles, composed of sterol and saponin from quillaja saponaria molina process for preparation and use thereof as carrier for amphipatic of hydrphobic molecules in fields of medicine including cancer treatment and food related compounds
AP2015008815A0 (en) 2013-04-25 2015-10-31 Crucell Holland Bv Stabilized soluble prefusion rsv f polypeptides
MX369317B (es) 2013-05-30 2019-11-05 Janssen Vaccines & Prevention Bv Vacunas contra el virus de la influenza y sus usos.
MY171210A (en) 2013-06-17 2019-10-02 Janssen Vaccines & Prevention Bv Stabilized soluble pre-fusion rsv f polypeptides
WO2015000831A1 (en) 2013-07-02 2015-01-08 Crucell Holland B.V. Method for preparing virosomes
EP3017040B1 (en) 2013-07-02 2018-06-06 Janssen Vaccines & Prevention B.V. Method for preparing virosomes
EP3046580A2 (en) 2013-09-19 2016-07-27 Zoetis Services LLC Oil-based adjuvants
DE102014005771A1 (de) 2014-04-23 2015-10-29 Clariant International Ltd. Verwendung von wässrigen driftreduzierenden Zusammensetzungen
CN106661091B (zh) 2014-07-10 2020-10-30 扬森疫苗与预防公司 流行性感冒病毒疫苗及其用途
MY181175A (en) 2014-11-04 2020-12-21 Janssen Vaccines & Prevention Bv Therapeutic hpv16 vaccines
US10478487B2 (en) 2015-01-16 2019-11-19 Zoetis Services Llc Foot-and-mouth disease vaccine
SI3283634T1 (sl) 2015-04-14 2019-08-30 Janssen Vaccines & Prevention B.V. Rekombinantni adenovirus, ki izraža dva transgena z dvosmernim promotorjem
JP7189014B2 (ja) 2015-07-07 2022-12-13 ヤンセン ファッシンズ アンド プリベンション ベーフェー Ｒｓｖに対するワクチン
EP3319634B1 (en) 2015-07-07 2019-08-21 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion rsv f polypeptides
EA037295B1 (ru) 2015-08-20 2021-03-05 Янссен Вэксинс Энд Превеншн Б.В. Терапевтические вакцины против hpv18
EP3344288A1 (en) 2015-09-02 2018-07-11 Janssen Vaccines & Prevention B.V. Stabilized viral class i fusion proteins
CN114617959A (zh) 2015-09-03 2022-06-14 诺瓦瓦克斯股份有限公司 具有改进的稳定性和免疫原性的疫苗组合物
AU2016379097C1 (en) 2015-12-23 2021-04-08 Pfizer Inc. RSV F protein mutants
JP7233928B2 (ja) 2016-04-05 2023-03-07 ヤンセン ファッシンズ アンド プリベンション ベーフェー Ｒｓｖに対するワクチン
DK3439672T3 (da) 2016-04-05 2021-02-15 Janssen Vaccines & Prevention Bv Stabiliserede opløselige præfusions-rsv-f-proteiner
CN109922829A (zh) 2016-05-02 2019-06-21 扬森疫苗与预防公司 治疗性hpv疫苗组合
DE202016003070U1 (de) 2016-05-09 2016-06-07 Clariant International Ltd. Stabilisatoren für Silikatfarben
KR102573534B1 (ko) 2016-05-12 2023-08-31 얀센 백신스 앤드 프리벤션 비.브이. 강력하고 균형 잡힌 양방향성 프로모터
ES2836598T3 (es) 2016-05-30 2021-06-25 Janssen Vaccines & Prevention Bv Proteínas F de RSV prefusión estabilizadas
WO2017207477A1 (en) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
CN109312362B (zh) 2016-06-20 2022-06-28 扬森疫苗与预防公司 有效和平衡的双向启动子
JP7229151B2 (ja) 2016-07-14 2023-02-27 ヤンセン ファッシンズ アンド プリベンション ベーフェー Ｈｐｖワクチン
CN109906411B (zh) 2016-11-04 2022-12-27 卡博特公司 含结晶聚酯和有机硅的纳米复合物
AU2018217935B2 (en) 2017-02-09 2020-04-30 Janssen Vaccines & Prevention B.V. Potent and short promoter for expression of heterologous genes
JP2020519663A (ja) 2017-05-17 2020-07-02 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． Ｒｓｖ感染に対する防御免疫を誘導するための方法及び組成物
US12083228B2 (en) 2017-07-24 2024-09-10 Novavax, Inc. Methods and compositions for treating respiratory disease
SG11202001458SA (en) 2017-09-15 2020-03-30 Janssen Vaccines & Prevention Bv Method for the safe induction of immunity against rsv
JP7317047B2 (ja) 2018-01-23 2023-07-28 ヤンセン ファッシンズ アンド プリベンション ベーフェー インフルエンザウイルスワクチン及びその使用
BR112020019108A2 (pt) 2018-03-19 2020-12-29 Novavax, Inc. Vacinas polivalentes de nanopartículas de influenza
GB201807303D0 (en) 2018-05-03 2018-06-20 London School Of Hygeine & Tropical Medicine Glyconjugate vaccines
SG11202010469QA (en) 2018-05-23 2020-11-27 Adc Therapeutics Sa Molecular adjuvant
WO2020099383A1 (en) 2018-11-13 2020-05-22 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
CA3137448A1 (en) 2019-04-25 2020-10-29 Janssen Vaccines & Prevention B.V. Recombinant influenza antigens
CN113950333A (zh) 2019-05-15 2022-01-18 扬森疫苗与预防公司 使用基于腺病毒的疫苗预防性治疗呼吸道合胞病毒感染
AU2020275455A1 (en) 2019-05-15 2021-12-09 Janssen Vaccines & Prevention B.V. Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine
KR20220057578A (ko) 2019-09-05 2022-05-09 얀센 백신스 앤드 프리벤션 비.브이. 인플루엔자 바이러스 백신 및 이의 용도
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
CN116096732A (zh) 2020-01-31 2023-05-09 贝斯以色列护理医疗中心有限公司 用于预防和治疗冠状病毒感染的组合物和方法-sars-cov-2疫苗
MX2022014162A (es) 2020-05-11 2023-02-23 Janssen Pharmaceuticals Inc Proteínas de fusión de la proteína de la espícula del coronavirus estabilizadas.
EP4149537A1 (en) 2020-05-11 2023-03-22 Janssen Pharmaceuticals, Inc. Rna replicon encoding a stabilized corona virus spike protein
KR20230009466A (ko) 2020-05-11 2023-01-17 얀센 파마슈티칼즈, 인코포레이티드 SARS-CoV-2 백신
IL299515A (en) 2020-06-29 2023-02-01 Janssen Vaccines & Prevention Bv Immune combination against respiratory syncytial virus infection
IL299459A (en) 2020-07-06 2023-02-01 Janssen Pharmaceuticals Inc Proteins fused to stabilized coronavirus spike proteins
JP2022060169A (ja) 2020-10-02 2022-04-14 ファイザー・インク Ｒｓｖ ｆタンパク質生産のための細胞培養工程
WO2022175479A1 (en) 2021-02-19 2022-08-25 Janssen Vaccines & Prevention B.V. Vaccine combinations against respiratory syncytial virus strain a and b infections
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
US20240228548A9 (en) 2021-02-19 2024-07-11 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv fb antigens
AU2022249741A1 (en) 2021-04-01 2023-09-21 Msd International Business Gmbh Stabilized pre-fusion piv3 f proteins
WO2023020939A1 (en) 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023047348A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceuticals, Inc. Stabilized corona virus spike protein fusion proteins
WO2023047349A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceuticals, Inc. Stabilized coronavirus spike protein fusion proteins
WO2023111725A1 (en) 2021-12-14 2023-06-22 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023110618A1 (en) 2021-12-16 2023-06-22 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion hmpv fusion proteins
WO2023196634A2 (en) 2022-04-08 2023-10-12 Flagship Pioneering Innovations Vii, Llc Vaccines and related methods
WO2023217988A1 (en) 2022-05-12 2023-11-16 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion hmpv fusion proteins
WO2024017682A1 (en) 2022-07-18 2024-01-25 Janssen Vaccines & Prevention B.V. Rsv immunogens
WO2024030856A2 (en) 2022-08-01 2024-02-08 Flagship Pioneering Innovations Vii, Llc Immunomodulatory proteins and related methods
WO2024061757A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Pre-fusion human piv1 f proteins
WO2024061759A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Stabilized coronavirus s proteins
WO2024061753A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Stabilized trimeric class i fusion proteins
WO2024074584A1 (en) 2022-10-06 2024-04-11 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion piv3 f proteins
WO2024104947A2 (en) 2022-11-14 2024-05-23 Janssen Vaccines & Prevention B.V. Influenza b virus vaccines and uses thereof
WO2024151583A2 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations Vii, Llc Vaccines and related methods
US20240252614A1 (en) 2023-01-18 2024-08-01 Pfizer Inc. Vaccines against respiratory diseases
US20240269263A1 (en) 2023-02-06 2024-08-15 Flagship Pioneering Innovations Vii, Llc Immunomodulatory compositions and related methods
WO2024175579A1 (en) 2023-02-21 2024-08-29 Janssen Vaccines & Prevention B.V. Stabilized trimeric rsv fusion proteins without a heterologous trimerzation domain

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5839376B2 (ja) * 1978-10-30 1983-08-30 富士通株式会社 イオン注入法
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
DE3775783D1 (de) * 1986-01-14 1992-02-20 Nederlanden Staat Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
NZ230747A (en) * 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
NL9002314A (nl) * 1990-10-23 1992-05-18 Nederlanden Staat Immunogene complexen, in het bijzonder iscoms.
AUPM873294A0 (en) * 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
SE9600647D0 (sv) 1996-02-21 1996-02-21 Bror Morein Ny användning
US6231859B1 (en) * 1996-12-02 2001-05-15 Aquila Biopharmaceuticals, Inc. Saponin adjuvant compositions
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
US6558670B1 (en) * 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof

Also Published As

Publication number Publication date
CA2529363A1 (en) 2005-01-13
AU2004254152B2 (en) 2009-10-29
US20220241408A1 (en) 2022-08-04
WO2005002620A1 (en) 2005-01-13
ES2331952T3 (es) 2010-01-21
NZ544299A (en) 2009-03-31
US20160184427A1 (en) 2016-06-30
US20150320858A1 (en) 2015-11-12
US20240024468A1 (en) 2024-01-25
CA2529363C (en) 2013-04-02
DK1648505T3 (da) 2009-12-21
EP1648505B1 (en) 2009-09-09
US20060239963A1 (en) 2006-10-26
BRPI0412444B8 (pt) 2021-05-25
AU2004254152A1 (en) 2005-01-13
BRPI0412444B1 (pt) 2016-06-14
US20200345840A1 (en) 2020-11-05
DE602004023089D1 (de) 2009-10-22
US20140335049A1 (en) 2014-11-13
JP4731475B2 (ja) 2011-07-27
BRPI0412444A (pt) 2006-09-19
SE0301998D0 (sv) 2003-07-07
US20180369368A1 (en) 2018-12-27
JP2007527386A (ja) 2007-09-27
US8821881B2 (en) 2014-09-02
ZA200600151B (en) 2007-01-31
EP1648505A1 (en) 2006-04-26
ATE442164T1 (de) 2009-09-15

Similar Documents

Publication Publication Date Title
PL1648505T3 (pl) Frakcja Quil A o niskiej toksyczności i jej zastosowanie
SG170127A1 (en) Vaccine compositions comprising a saponin adjuvant
MX360448B (es) Adyuvantes sinteticos de glucopiranosil-lipido.
WO2007109812A3 (en) Immunopotentiating compounds
MY137619A (en) 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
WO2000062800A3 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
MX2010001054A (es) Composiciones adyuvantes antigenicas y metodos.
WO2006086449A3 (en) Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines
WO2006031878A3 (en) Imidazoquinoline compounds
MXPA05013973A (es) Metodos para producir, mejorar y sustentar respuestas inmunes contra epitopes restringidos mhc clase i, para propositos profilacticos o terapeuticos.
TR200002930T2 (tr) Kolaylaştırıcı kompozisyonlar
BRPI0607840A2 (pt) uso de uma composição imunogência, e de um antìgeno de vzv, vacina ou composição imunogênica, e, kit
WO2014205199A3 (en) Compositions and methods for potentiating immune response, enhancing immunotherapy, and increasing vaccine potency
BRPI0621181A8 (pt) Substâncias imunogênicas que compreendem um adjuvante a base de ácido poliinosínico - ácido policitidílico
WO2006062807A3 (en) Compositions with enhanced immunogenicity
BR122018075729B8 (pt) flavivírus na preparação de uma composição de vacina
AU5162201A (en) Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and qs-21
BRPI0513288A (pt) uso de alcanóis fosfatados como dispersantes, emulsificantes, hodrótropos, agentes umectantes e agentes de compatabilidade em composições agriculturais
WO1996009805A3 (en) Chitosan induced immunopotentiation
MX2007002531A (es) Derivados novedosos de 3,5-seco-4-norcolestan y usos de los mismos.
WO2006114680A8 (en) Vaccine adjuvants
WO2002053176A3 (en) An autologous anti-cancer vaccine
WO2000057908A3 (en) Attenuated dengue-1 virus vaccine
MY150842A (en) Cocoa extract for use in providing skin benefits
MY127452A (en) Vaccines.